
    
      The MTD and biochemically active dose of FUDR as a 24-hour and gemcitabine as a 2-hour
      infusion will be determined first (Part A); if the biochemically active FUDR dose is less
      than the MTD, new patients will be entered to determine the maximum tolerated duration of
      FUDR infusion (Part B).
    
  